Senti Biosciences

Timothy Lu, M.D., Ph.D., Co-founder and CEO

Oct. 11 | 5:30pm | UBC Ballroom  

San Francisco, CA 

(NASDAQ: SNTI) 

In-person Presentation 

Senti Biosciences’ mission is to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. To accomplish this, we are building a synthetic biology platform that may enable us to program next-generation cell and gene therapies with what we refer to as Gene Circuits. These Gene Circuits, which are created from novel and proprietary combinations of DNA sequences, are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to their cellular environments. Our synthetic biology platform utilizes off-the-shelf CAR-NK cells, outfitted with these Gene Circuit technologies, to target particularly challenging oncology indications. Our lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells while sparing the healthy bone marrow, and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of Hepatocellular Carcinoma (HCC). 

www.sentibio.com 



By using this website you agree to accept our Privacy Policy and Terms & Conditions